Acadia Pharmaceuticals (ACAD) EBITDA (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly EBITDA of -$4.6 million for Q1 2026, down 123.93% year-over-year from $19.3 million in Q1 2025, and down 126.54% quarter-over-quarter from $17.4 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) EBITDA (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' EBITDA history runs 17 years deep, the most recent figure standing at -$4.6 million for Q1 2026.
- In Q1 2026, EBITDA fell 123.93% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at $80.9 million (down 65.55% YoY), while the FY2025 annual figure was $104.8 million, down 54.59% from the prior year.
- EBITDA for Q1 2026 stood at -$4.6 million, down from $17.4 million in the prior quarter.
- The five-year high for EBITDA was $153.5 million in Q4 2024, with the low at -$113.0 million in Q1 2022.
- The 5-year median for EBITDA is $15.2 million (2024), against an average of $2.0 million.
- The sharpest annual moves came in 2024 and 2026: EBITDA jumped 902.21% in 2024, then slumped 123.93% in 2026.
- Acadia Pharmaceuticals' EBITDA stood at -$46.1 million in 2022, then jumped by 175.86% to $34.9 million in 2023, then soared by 339.28% to $153.5 million in 2024, then slumped by 88.67% to $17.4 million in 2025, then sank by 126.54% to -$4.6 million in 2026.
- Business Quant data shows ACAD's EBITDA at -$4.6 million in Q1 2026, $17.4 million in Q4 2025, and $35.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 37.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.84 Mn |
| Mar 31, 2026 | -4.62 Mn |
| Dec 31, 2025 | 17.39 Mn |
| Sep 30, 2025 | 35.76 Mn |
| Jun 30, 2025 | 32.37 Mn |
| Mar 31, 2025 | 19.29 Mn |
| Dec 31, 2024 | 153.50 Mn |
| Sep 30, 2024 | 31.64 Mn |
| Jun 30, 2024 | 30.44 Mn |
| Mar 31, 2024 | 15.21 Mn |
| Dec 31, 2023 | 34.94 Mn |
| Sep 30, 2023 | -57.78 Mn |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | -53.58 Mn |
| Dec 31, 2022 | -46.06 Mn |
| Sep 30, 2022 | -30.87 Mn |
| Jun 30, 2022 | -33.65 Mn |
| Mar 31, 2022 | -113.02 Mn |
| Dec 31, 2021 | -44.66 Mn |
| Sep 30, 2021 | -15.30 Mn |